Article
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Hepatology (Baltimore, Md.) - 1 Feb 2018
Wyles David, Poordad Fred, Wang Stanley, Alric Laurent, Felizarta Franco, Kwo Paul Y, Maliakkal Benedict, Agarwal Kosh, Hassanein Tarek, Weilert Frank, Lee Samuel S, Kort Jens, Lovell Sandra S, Liu Ran, Lin Chih-Wei, Pilot-Matias Tami, Krishnan Preethi, Mensa Federico J
Abstract excerpt
This study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options. SURVEYOR-II, Part 3 was a partially randomized, open-label, multicenter, phase 3 study. Treatment-experienced (prior interferon or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.